Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial
Articolo
Data di Pubblicazione:
2004
Citazione:
Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer:
A Randomized Trial / G. Bolis, G. Scarfone, G. Polverino, F. Raspagliesi, S. Tateo,
G. Richiardi, M. Melpignano, M. Franchi, G. Mangili, M. Presti,
A. Villa, E. Conta, P. Guarnerio, S. Cipriani, F. Parazzini. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 22:4(2004 Feb), pp. 686-690. [10.1200/JCO.2004.03.017]
Abstract:
Purpose
To analyze the effect of different doses of paclitaxel with fixed doses of carboplatin in the treatment of
ovarian cancer.
Patients and Methods
Patients with histologically confirmed epithelial ovarian cancer, International Federation of Gynecology
and Obstetrics stages IIB to IV, were eligible for this randomized, multicenter study. Women were
randomly assigned to treatment with (1) carboplatin at the dose (in milligrams) corresponding to the
following formula: target area under the free carboplatin plasma concentration versus time curve (AUC)
6 (glomerular filtration rate 25) mg/m2 (AUC6) plus paclitaxel 175 mg/m2 for six cycles every 21
days or (2) carboplatin AUC6 plus paclitaxel 225 mg/m2 for six cycles every 21 days. A total of 502
women entered the study.
Results
Pathologic complete response was documented in 132 patients (63.8%) in the 175 mg/m2 group and in
127 cases (55.7%) in the 225 mg/m2 group ( 2 P .090). The 4-year progression-free survival rate was
41.5% (SE 3.5) in the 175-mg group and 39.2% (SE 3.5) in the 225-mg group. The corresponding
4-year survival rates were 46.2% (based on 115 deaths) and 47.3% (based on 113 deaths), respectively.
Conclusion
This randomized trial suggests that paclitaxel 175 mg/m2 plus carboplatin AUC6 is the schedule with a
more favorable profile than paclitaxel 225 mg/m2 plus carboplatin AUC6.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
G. Bolis, G. Scarfone, G. Polverino, F. Raspagliesi, S. Tateo, G. Richiardi, M. Melpignano, M. Franchi, G. Mangili, M. Presti, A. Villa, E. Conta, P. Guarnerio, S. Cipriani, F. Parazzini
Link alla scheda completa: